These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 9787317

  • 1. Intermediate dose methotrexate is as effective as high dose methotrexate in preventing isolated testicular relapse in childhood acute lymphoblastic leukemia.
    Dördelmann M, Reiter A, Zimmermann M, Fengler R, Henze G, Riehm H, Schrappe M.
    J Pediatr Hematol Oncol; 1998; 20(5):444-50. PubMed ID: 9787317
    [Abstract] [Full Text] [Related]

  • 2. Prevention of CNS recurrence in childhood ALL: results with reduced radiotherapy combined with CNS-directed chemotherapy in four consecutive ALL-BFM trials.
    Schrappe M, Reiter A, Henze G, Niemeyer C, Bode U, Kühl J, Gadner H, Havers W, Plüss H, Kornhuber B, Zintl F, Ritter J, Urban C, Niethammer D, Riehm H.
    Klin Padiatr; 1998; 210(4):192-9. PubMed ID: 9743952
    [Abstract] [Full Text] [Related]

  • 3. Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster-based intensive chemotherapy. The Associazione Italiana di Ematologia ed Oncologia Pediatrica.
    Conter V, Aricò M, Valsecchi MG, Rizzari C, Testi AM, Messina C, Mori PG, Miniero R, Colella R, Basso G.
    J Clin Oncol; 1995 Oct; 13(10):2497-502. PubMed ID: 7595699
    [Abstract] [Full Text] [Related]

  • 4. Importance of effective central nervous system therapy in isolated bone marrow relapse of childhood acute lymphoblastic leukemia. BFM (Berlin-Frankfurt-Münster) Relapse Study Group.
    Bührer C, Hartmann R, Fengler R, Schober S, Arlt I, Loewke M, Henze G.
    Blood; 1994 Jun 15; 83(12):3468-72. PubMed ID: 8204875
    [Abstract] [Full Text] [Related]

  • 5. Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.
    Millot F, Suciu S, Philippe N, Benoit Y, Mazingue F, Uyttebroeck A, Lutz P, Mechinaud F, Robert A, Boutard P, Marguerite G, Ferster A, Plouvier E, Rialland X, Behard C, Plantaz D, Dresse MF, Philippet P, Norton L, Thyss A, Dastugue N, Waterkeyn C, Vilmer E, Otten J, Children's Leukemia Cooperative Group of the European Organiztaion for Research and Treatment of Cancer.
    J Clin Oncol; 2001 Apr 01; 19(7):1935-42. PubMed ID: 11283125
    [Abstract] [Full Text] [Related]

  • 6. Methotrexate infusions as central nervous system prophylaxis in children with acute lymphocytic leukemia: the Norwegian experience.
    Moe PJ, Holen A, Nygaard R, Glomstein A, Madsen B, Hellebostad M, Stokland T, Wefring KW, Steen-Johnsen J, Nielsen B, Hapnes C, Børsting S.
    Pediatr Hematol Oncol; 2003 Apr 01; 20(3):187-200. PubMed ID: 12637215
    [Abstract] [Full Text] [Related]

  • 7. Randomized comparison of 36-hour intermediate-dose versus 4-hour high-dose methotrexate infusions for remission induction in relapsed childhood acute lymphoblastic leukemia.
    Wolfrom C, Hartmann R, Fengler R, Brühmüller S, Ingwersen A, Henze G.
    J Clin Oncol; 1993 May 01; 11(5):827-33. PubMed ID: 8487046
    [Abstract] [Full Text] [Related]

  • 8. Role of cranial radiotherapy for childhood T-cell acute lymphoblastic leukemia with high WBC count and good response to prednisone. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Münster groups.
    Conter V, Schrappe M, Aricó M, Reiter A, Rizzari C, Dördelmann M, Valsecchi MG, Zimmermann M, Ludwig WD, Basso G, Masera G, Riehm H.
    J Clin Oncol; 1997 Aug 01; 15(8):2786-91. PubMed ID: 9256120
    [Abstract] [Full Text] [Related]

  • 9. Effective preventive central nervous system therapy with extended triple intrathecal therapy and the modified ALL-BFM 86 chemotherapy program in an enlarged non-high risk group of children and adolescents with non-B-cell acute lymphoblastic leukemia: the Israel National Study report.
    Stark B, Sharon R, Rechavi G, Attias D, Ballin A, Cividalli G, Burstein Y, Sthoeger D, Abramov A, Zaizov R.
    Cancer; 2000 Jan 01; 88(1):205-16. PubMed ID: 10618625
    [Abstract] [Full Text] [Related]

  • 10. Response of children with high-risk acute lymphoblastic leukemia treated with and without cranial irradiation: a report from the Children's Cancer Group.
    Nachman J, Sather HN, Cherlow JM, Sensel MG, Gaynon PS, Lukens JN, Wolff L, Trigg ME.
    J Clin Oncol; 1998 Mar 01; 16(3):920-30. PubMed ID: 9508174
    [Abstract] [Full Text] [Related]

  • 11. Six-year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL-REZ BFM 85). A relapse study of the BFM group.
    Henze G, Fengler R, Hartmann R, Kornhuber B, Janka-Schaub G, Niethammer D, Riehm H.
    Blood; 1991 Sep 01; 78(5):1166-72. PubMed ID: 1878583
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Prophylaxis and treatment of neoplastic meningeosis in childhood acute lymphoblastic leukemia.
    Schrappe M, Reiter A, Riehm H.
    J Neurooncol; 1998 Sep 01; 38(2-3):159-65. PubMed ID: 9696367
    [Abstract] [Full Text] [Related]

  • 14. Prevention of CNS disease in intermediate-risk acute lymphoblastic leukemia: comparison of cranial radiation and intrathecal methotrexate and the importance of systemic therapy: a Childrens Cancer Group report.
    Tubergen DG, Gilchrist GS, O'Brien RT, Coccia PF, Sather HN, Waskerwitz MJ, Hammond GD.
    J Clin Oncol; 1993 Mar 01; 11(3):520-6. PubMed ID: 8445427
    [Abstract] [Full Text] [Related]

  • 15. Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Children's Oncology Group AALL0434 Methotrexate Randomization.
    Winter SS, Dunsmore KP, Devidas M, Wood BL, Esiashvili N, Chen Z, Eisenberg N, Briegel N, Hayashi RJ, Gastier-Foster JM, Carroll AJ, Heerema NA, Asselin BL, Gaynon PS, Borowitz MJ, Loh ML, Rabin KR, Raetz EA, Zweidler-Mckay PA, Winick NJ, Carroll WL, Hunger SP.
    J Clin Oncol; 2018 Oct 10; 36(29):2926-2934. PubMed ID: 30138085
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Improvement in CNS protective treatment in non-high-risk childhood acute lymphoblastic leukemia: report from the Japanese Children's Cancer and Leukemia Study Group.
    Tsurusawa M, Katano N, Yamamoto Y, Hirota T, Koizumi S, Watanabe A, Takeda T, Hatae Y, Yatabe M, Mimaya J, Gushiken T, Nishi K, Anami K, Kikuta A, Kanegane H, Asami K, Nishikawa K, Sekine I, Kawano Y, Iwai A, Furuyama T, Ijichi O, Miyake M, Mugishima H, Fujimoto T.
    Med Pediatr Oncol; 1999 Apr 10; 32(4):259-6. PubMed ID: 10102019
    [Abstract] [Full Text] [Related]

  • 18. 6-mercaptopurine dosage and pharmacokinetics influence the degree of bone marrow toxicity following high-dose methotrexate in children with acute lymphoblastic leukemia.
    Schmiegelow K, Bretton-Meyer U.
    Leukemia; 2001 Jan 10; 15(1):74-9. PubMed ID: 11243403
    [Abstract] [Full Text] [Related]

  • 19. Peripheral blast counts at diagnosis of late isolated bone marrow relapse of childhood acute lymphoblastic leukemia predict response to salvage chemotherapy and outcome. Berlin-Frankfurt-Münster Relapse Study Group.
    Bührer C, Hartmann R, Fengler R, Rath B, Schrappe M, Janka-Schaub G, Henze G.
    J Clin Oncol; 1996 Oct 10; 14(10):2812-7. PubMed ID: 8874343
    [Abstract] [Full Text] [Related]

  • 20. Favorable outcome of B-cell acute lymphoblastic leukemia in childhood: a report of three consecutive studies of the BFM group.
    Reiter A, Schrappe M, Ludwig WD, Lampert F, Harbott J, Henze G, Niemeyer CM, Gadner H, Müller-Weihrich S, Ritter J.
    Blood; 1992 Nov 15; 80(10):2471-8. PubMed ID: 1421370
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.